Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic About its Expanded DehydraTECH Investigations; Plans for More Studies in 2022
Lexaria just announced ground-breaking findings from its recently-concluded Sildenafil animal studyThe success of this study sets the stage for various other studies on the use of the company’s patented DehydraTECH technologyThe company is set to commence dosing its most extensive hypertension study in April 2022, with results expected in Q3 2022Its successful completion could greatly enhance Lexaria’s leadership position in the global drug delivery market…